Breaking News

Financial Report: Gilead

July 26, 2013

Revenues climb 15% in the quarter


2Q Revenues: $2.7 billion (+15%)

2Q Earnings: $767.6 million (+9%)

YTD Revenues: $5.1 billion (+12%)

YTD Earnings: $1.5 billion (+30%)

Comments: Antiviral product sales were up 15% to $2.3 billion in the quarter, driven by Viread, up 16% to $250.2 million, and Complera/Eviplera, up 159% to $188.7 million, along with Atripla sales, up 4% to $938.1 million, Truvada sales, up 3% to $807.8 million. Additionally, the company launched Stribild, which generated $99.4 million in sales. Cardiovascular product sales (Letairis and Ranexa) were $234.9 million in the quarter, up 19%. Royalty, contract and other revenues were $110.1 million, up 31%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks